Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
Open Access
- 1 February 2002
- journal article
- research article
- Published by SAGE Publications in Vascular Medicine
- Vol. 7 (1) , 35-43
- https://doi.org/10.1191/1358863x02vm412ra
Abstract
Based on the data from large single and multi-center clinical trials, including the Heart Outcomes Prevention Evaluation (HOPE) study, it is clear that the presence of microalbuminuria is a signal from the kidney that cardiovascular risk is increased and that vascular responses are altered. This is exemplified by studies that have demonstrated that the compensatory vaso-dilation seen following relief from prolonged ischemia or infusion of vasodilators such as nitroglycerin is blunted in people with microalbuminuria. Thus, the presence of between 30 and 299 mg/day of albumin in the urine is associated with abnormal vascular responsiveness, which may be the result of more advanced atherosclerosis and not necessarily related to the presence of hypertension or renal disease. Agents known to reduce the rise in microalbuminuria or actually reduce the level of microalbuminuria, such as ACE inhibitors, angiotensin receptor blockers, HMG-CoA reductase inhibitors, beta blockers, non-dihydropyridine calcium channel blockers and diuretics, have all been shown to reduce cardiovascular mortality and in some cases preserve renal function. This article will present an overview of the data that support the assertion that a reduction in the rise of microalbuminuria is a significant consideration in the selection of agents to treat a given risk factor (cholesterol or blood pressure) to a recommended target goal. Achieving such a goal with agents that also impact microalbuminuria will provide for a more complete cardiovascular risk reduction.Keywords
This publication has 77 references indexed in Scilit:
- Effect of lipid reduction on the progression of renal disease: A meta-analysisKidney International, 2001
- Prevalence and Clinical Correlates of Microalbuminuria in Essential HypertensionHypertension, 1997
- Microalbuminuria and Carotid Artery Intima-Media Thickness in Nondiabetic and NIDDM SubjectsStroke, 1997
- Renal and Systemic Transvascular Albumin Leakage in Severe AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- The Natural Course of Microalbuminuria in Insulin‐dependent Diabetes: A 10‐year Prospective StudyDiabetic Medicine, 1995
- Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the scientific advisory board of the nationals Kidney Foundation from an Ad Hoc Committee of the council on diabetes mel of the national kidney foundationAmerican Journal of Kidney Diseases, 1995
- Effects of Long-Term Enalapril Treatment on Persistent Microalbuminuria in Well-Controlled Hypertensive and Normotensive NIDDM PatientsDiabetes Care, 1994
- Microalbuminuria: Implications for micro- and macrovascular diseaseDiabetes Care, 1992
- Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset DiabetesNew England Journal of Medicine, 1984
- MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUSThe Lancet, 1982